RhumbLine Advisers
DFTX

RhumbLine Advisers’s Definium Therapeutics DFTX Stock Holding History

RhumbLine Advisers’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Buy
119,972
+9,225
+8% +$157K ﹤0.01% 1779
2025
Q4 		$1.48M Sell
110,747
-1,371
-1% -$17K ﹤0.01% 2034
2025
Q3 		$1.32M Sell
112,118
-3,178
-3% -$29.6K ﹤0.01% 2103
2025
Q2 		$748K Buy
115,296
+6,839
+6% +$45K ﹤0.01% 2402
2025
Q1 		$634K Buy
108,457
+7,762
+8% +$55.6K ﹤0.01% 2415
2024
Q4 		$701K Buy
100,695
+4,868
+5% +$33.5K ﹤0.01% 2454
2024
Q3 		$545K Buy
95,827
+1,711
+2% +$11.9K ﹤0.01% 2645
2024
Q2 		$679K Buy
+94,116
New +$823K ﹤0.01% 2460
2022
Q2 		– Sell
-20,112
Closed -$335K – 3185
2022
Q1 		$335K Sell
20,112
-551
-3% -$9.56K ﹤0.01% 2602
2021
Q4 		$428K Buy
20,663
+183
+0.9% +$5.84K ﹤0.01% 2574
2021
Q3 		$716K Buy
20,480
+992
+5% +$42.9K ﹤0.01% 2383
2021
Q2 		$1.01M Buy
+19,488
New +$1.02M ﹤0.01% 2243

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RhumbLine Advisers's DFTX Position: Q1 2026 in Review

RhumbLine Advisers increased its Definium Therapeutics (DFTX) stake by 8.3% in Q1 2026, buying an estimated $157K and bringing the position to 119,972 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1779.

RhumbLine Advisers first reported a position in DFTX in Q2 2021 and has held it in 12 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • RhumbLine Advisers held 119,972 shares of Definium Therapeutics worth $2.27M as of Q1 2026.
  • RhumbLine Advisers bought 9,225 Definium Therapeutics shares in Q1 2026, an estimated $157K.
  • Definium Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1779 holding.
  • RhumbLine Advisers first reported a position in Definium Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.